# A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

> **NCT05593666** · PHASE2 · COMPLETED · sponsor: **Drugs for Neglected Diseases** · enrollment: 101 (actual)

## Conditions studied

- Primary Visceral Leishmaniasis

## Interventions

- **DRUG:** LXE408
- **OTHER:** Placebo
- **DRUG:** AmBisome®

## Key facts

- **NCT ID:** NCT05593666
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-27
- **Primary completion:** 2025-04-15
- **Final completion:** 2025-12-22
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593666, "A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05593666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*